The proposed sale is small relative to market cap and the insider's holdings. The insider has been a consistent seller in recent weeks, but the amounts are not large enough to signal a change in outlook. Monitor for any acceleration in insider selling or a Form 4 filing confirming the transaction.
LGND drugs
LGND drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $314.16entry
- T+1 · 6d ago +0.85%α −0.47% · $316.83
- T+4 · todayOpen
- T+5 · in 5h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Jason Aryeh filed a Form 144 notice to sell 3,000 shares of Ligand Pharmaceuticals Class B common stock, with an estimated aggregate market value of approximately $960,084. The shares were acquired in 2019 via secondary market purchases. This is a relatively small sale relative to the company's $6.1B market cap and the insider's apparent holdings, and the filing signals intent to sell rather than a completed transaction.
Key Facts
- Director Jason Aryeh filed Form 144 to sell 3,000 shares of Class B common stock
- Estimated aggregate market value of the proposed sale is $960,084.19
- Shares were acquired between May 14, 2019 and July 30, 2019 via secondary market purchases
- The proposed sale date is November 10, 2026 on Nasdaq
- The insider has sold 2,193 shares in three separate transactions between October 30 and November 4, 2026, totaling approximately $671,558
Financial Impact
Proposed sale of 3,000 shares valued at ~$960K, representing a small fraction of the insider's apparent holdings and less than 0.02% of the company's $6.1B market cap
Risk Factors
- Form 144 is only an intent to sell; the sale may not be executed
- The insider has sold shares in multiple transactions over the past two weeks, which could indicate a pattern of routine portfolio diversification
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001957799-26-000200 |
| Document: 0001957799-26-000200-index.html | 0001957799-26-000200 |
| Document: 0001957799-26-000200.txt | 0001957799-26-000200 |
Track record
29 reports on LGND
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Viewing Entry $314.16 Now $301.71 −3.96% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers